

Synthesis, antimicrobial, and anti-HIV-1 activity of certain 5-(1-adamantyl)-2-substituted thio-1,3,4-oxadiazoles and 5-(1-adamantyl)-3-substituted aminomethyl-1,3,4-oxadiazoline-2-thiones

Ali A. El-Emam,^{a,*} Omar A. Al-Deeb,^a Mohamed Al-Omar^a and Jochen Lehmann^b

^aDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

^bLehrstuhl für Pharmazeutische Chemie/Medizinische Chemie, Institut für Pharmazie, Friedrich-Schiller-Universität Jena, D-07743 Jena, Germany

Received 14 June 2004; revised 14 July 2004; accepted 15 July 2004

Available online 7 August 2004

Abstract—The reaction of 5-(1-adamantyl)-1,3,4-oxadiazoline-2-thione **2** with iodoethane, 2-dimethylaminoethyl chloride hydrochloride or 2-piperidinoethyl chloride hydrochloride in ethanolic potassium hydroxide yielded the corresponding 5-(1-adamantyl)-2-ethyl or substituted ethylthio-1,3,4-oxadiazoles **3a–c**. Interaction of **2** with formaldehyde solution and primary aromatic amines or 1-substituted piperazines, in ethanol at room temperature yielded the corresponding 5-(1-adamantyl)-3-arylaminomethyl-1,3,4-oxadiazoline-2-thiones **4a–m** or 5-(1-adamantyl)-3-(4-substituted-1-piperazinylmethyl)-1,3,4-oxadiazoline-2-thiones **5a–h**, respectively. All the synthesized compounds were tested for in vitro activities against certain strains of Gram-positive and Gram-negative bacteria and the yeast-like pathogenic fungus *Candida albicans*. Compounds **2**, **5a**, and **5e** were found as the most active derivatives, particularly against the Gram-positive bacteria. In addition, the antiviral activity of compounds **2**, **4a–m**, and **5a–h** against HIV-1 using the XTT assay was carried out. Compound **2** produced 100%, 43%, and 37% reduction of viral replication at 50, 10, and 2 µg/mL concentrations, respectively.

© 2004 Elsevier Ltd. All rights reserved.

1. Introduction

A number of adamantane derivatives have long been known for their antiviral activity against Influenza A^{1–6} and HIV viruses.^{7–9} Several adamantane derivatives were also associated with central nervous,^{10–14} antimicrobial,^{15–19} and anti-inflammatory activities.^{20–24} In addition, 1,3,4-oxadiazole derivatives were reported to possess significant antibacterial^{25,26} and anti-inflammatory activities.^{27,28} Moreover, several bis(heteroaryl)piperazine derivatives (BHAP) were introduced as potent antiviral drugs.^{29,30} In continuation to our interest in the chemical and pharmacological properties of adamantane derivatives,^{19,23,31–33} we report herein the synthesis, antimicrobial, and anti-HIV-1 activity of new series of 5-(1-adamantyl)-2-substituted ethylthio-1,3,4-oxadiazoles, 5-(1-adamantyl)-3-arylaminomethyl-1,3,4-oxadiaz-

oline-2-thiones, and 5-(1-adamantyl)-3-(4-substituted-1-piperazinylmethyl)-1,3,4-oxadiazoline-2-thiones.

2. Results and discussion

2.1. Chemistry

The starting material adamantane-1-carbohydrazide **1**³⁴ was obtained via prolonged heating of methyl adamantane-1-carboxylate²⁰ with hydrazine. The hydrazide **1** was reacted with carbon disulfide and potassium hydroxide, in ethanol, followed by acidification to yield 5-(1-adamantyl)-1,3,4-oxadiazoline-2-thione **2** in 81% yield. Interaction of **2** with iodoethane, 2-dimethylaminoethyl chloride, or 2-(1-piperidyl)ethyl chloride hydrochloride in ethanolic potassium hydroxide yielded the corresponding 5-(1-adamantyl)-2-ethylthio or substituted ethylthio-1,3,4-oxadiazoles **3a–c**. On the other hand, the *N*-Mannich derivatives 5-(1-adamantyl)-3-arylaminomethyl-1,3,4-oxadiazoline-2-thiones **4a–m** and


* Corresponding author. Tel.: +966-1-4677350; fax: +966-1-4676220; e-mail: elemam5@hotmail.com

5-(1-adamantyl)-3-(4-substituted-1-piperazinylmethyl)-1,3,4-oxadiazoline-2-thiones **5a–h**, were prepared in high yields via the reaction of **2** with formaldehyde solution and the corresponding primary aromatic amine or 1-substituted piperazine, in ethanol at room temperature, respectively (Scheme 1, Table 1). The structures of the synthesized compounds were confirmed by elemental analyses, IR, ^1H NMR, ^{13}C NMR, and EI mass spectral data.

2.2. In vitro antimicrobial activity

The synthesized compounds were tested for their in vitro antimicrobial activity against the Gram-positive bacteria *Staphylococcus aureus* ATCC 19433 and *Bacillus subtilis* ATCC 6633, the Gram-negative bacteria *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853, and the yeast-like pathogenic fungus *Candida albicans* ATCC 753. The primary screen was carried out using the agar disc-diffusion method³⁵ using Müller–Hinton agar medium. Sterile filter paper discs

(8 mm diameter) were moistened with the test compound solution in dimethylsulfoxide of specific concentration 200 $\mu\text{g}/\text{disc}$ were carefully placed on the agar cultures plates that had been previously inoculated separately with the microorganisms. The plates were incubated at 37°C, and the diameter of the growth inhibition zones were measured after 24 h in case of bacteria and 48 h in case of *C. albicans*. The results of the preliminary antimicrobial testing of the prepared compounds, the typical broad spectrum antibacterial drug ciprofloxacin and the potent antifungal drug clotrimazole (100 $\mu\text{g}/\text{disc}$) are shown in Table 2. The results revealed that majority of the synthesized compounds showed varying degrees of inhibition against the tested microorganisms. In general, the inhibitory activity against the tested Gram-positive bacteria was higher than that of the Gram-negative bacteria, and some derivatives showed moderate or weak activity against *C. albicans*. The ethylthio and the aminoethylthio derivatives **3a–c** were almost inactive. The compounds **2**, **5a**, and **5e** showed broad spectrum antimicrobial activity, they possessed



Scheme 1.

Table 1. Crystallization solvents, melting points, yield percentages, molecular formulae, and molecular weights of compounds **3a–c**, **4a–m**, and **5a–h**

Compound no.	R	Cryst. solvent	Mp (°C)	Yield (%)	Mol. Formula (Mol. Wt)
3a	H	EtOH/H ₂ O	53–55	82	C ₁₄ H ₂₀ N ₂ OS (264.38)
3b	N(CH ₃) ₂	EtOH/H ₂ O	76–78	72	C ₁₆ H ₂₅ N ₃ OS (307.45)
3c	1-Piperidyl	EtOH/H ₂ O	73–75	77	C ₁₉ H ₂₉ N ₃ OS (347.51)
4a	H	EtOH	141–143	88	C ₁₉ H ₂₃ N ₃ OS (341.47)
4b	2-F	EtOH	109–111	81	C ₁₉ H ₂₂ FN ₃ OS (359.46)
4c	4-F	EtOH	140–142	90	C ₁₉ H ₂₂ FN ₃ OS (359.46)
4d	2-Cl	EtOH	135–137	87	C ₁₉ H ₂₂ ClN ₃ OS (375.91)
4e	4-Cl	EtOH	177–179	92	C ₁₉ H ₂₂ ClN ₃ OS (375.91)
4f	2-Br	EtOH	144–146	79	C ₁₉ H ₂₂ BrN ₃ OS (420.36)
4g	4-Br	EtOH/CHCl ₃	170–172	82	C ₁₉ H ₂₂ BrN ₃ OS (420.36)
4h	3-NO ₂	EtOH/CHCl ₃	150–152	73	C ₁₉ H ₂₂ N ₄ O ₃ S (386.46)
4i	4-NO ₂	EtOH/CHCl ₃	231–233	69	C ₁₉ H ₂₂ N ₄ O ₃ S (386.46)
4j	4-CH ₃ O	EtOH	131–133	88	C ₂₀ H ₂₅ N ₃ O ₂ S (371.49)
4k	2-CN	EtOH/H ₂ O	174–176	75	C ₂₀ H ₂₂ N ₄ OS (366.48)
4l	2-CF ₃	EtOH	148–150	80	C ₂₀ H ₂₂ F ₃ N ₃ OS (409.46)
4m	2,5-F ₂	EtOH/CHCl ₃	130–132	88	C ₁₉ H ₂₁ F ₂ N ₃ OS (377.45)
5a	CH ₃	EtOH/H ₂ O	113–115	64	C ₁₈ H ₂₈ N ₄ OS (348.50)
5b	C ₂ H ₅	EtOH/H ₂ O	109–111	61	C ₁₉ H ₃₀ N ₄ OS (362.53)
5c	COOC ₂ H ₅	EtOH/H ₂ O	118–120	76	C ₂₀ H ₃₀ N ₄ O ₃ S (406.54)
5d	C ₆ H ₅	EtOH	166–168	89	C ₂₃ H ₃₀ N ₄ OS (410.57)
5e	4-FC ₆ H ₄	EtOH	180–182	92	C ₂₃ H ₂₉ FN ₄ OS (428.56)
5f	2-CH ₃ OC ₆ H ₄	EtOH	142–144	82	C ₂₄ H ₃₂ N ₄ O ₂ S (440.60)
5g	C ₆ H ₅ CH ₂	EtOH	127–129	75	C ₂₄ H ₃₂ N ₄ OS (424.60)
5h	2-CF ₃ C ₆ H ₄ CH ₂	EtOH	152–154	85	C ₂₅ H ₃₁ F ₃ N ₄ OS (492.60)

Table 2. Antimicrobial activity of compounds **2**, **3a–c**, **4a–m**, **5a–h** (200 µg/8 mm disc), the broad spectrum antibacterial drug Ciprofloxacin (100 µg/8 mm disc) and the antifungal drug Clotrimazole (100 µg/8 mm disc) against *S. aureus* ATCC 19433 (*SA*), *B. subtilis* ATCC 6633 (*BS*), *E. coli* ATCC 25922 (*EC*), *P. aeruginosa* ATCC 27853 (*PA*), and *C. albicans* ATCC 753 (*CA*)

Compound no.	Diameter of growth inhibition zone (mm) ^a				
	<i>SA</i>	<i>BS</i>	<i>EC</i>	<i>PA</i>	<i>CA</i>
2	23	23	18	16	14
3a	—	—	—	—	—
3b	9	—	—	—	—
3c	10	10	—	—	—
4a	12	14	9	10	—
4b	14	11	8	—	—
4c	17	16	10	10	—
4d	15	12	10	9	—
4e	18	18	11	9	—
4f	10	8	—	—	—
4g	12	10	—	—	—
4h	10	11	—	—	—
4i	14	12	10	10	—
4j	12	9	—	—	—
4k	8	10	—	—	—
4l	19	16	12	13	10
4m	18	18	11	13	10
5a	24	22	17	18	15
5b	19	17	10	10	10
5c	11	9	—	—	—
5d	18	18	10	13	9
5e	21	19	16	14	12
5f	18	19	14	13	10
5g	16	17	10	11	—
5h	17	16	10	10	9
Ciprofloxacin	22	22	25	19	NT
Clotrimazole	NT	NT	NT	NT	23

^a (—): Inactive, no inhibition zone. (NT): Not tested.

excellent activity against the Gram-positive bacteria (inhibition zone >20 mm), good activity against the Gram-negative bacteria (inhibition zone 14–18 mm), and moderate activity against *C. albicans* (inhibition zone 12–15 mm). The minimal inhibitory concentration (MIC) for the most active compounds **2**, **4c,e,l,m**, **5a,b,d–h** against the same microorganism used in the primary screening was carried out using the microdilution susceptibility method in Müller–Hinton Broth and Sabouraud Liquid Medium.³⁶ The compounds, ciprofloxacin and clotrimazole were dissolved in dimethylsulfoxide at concentration of 800 µg/mL. The twofold dilutions of the solution was prepared (400, 200, 100, ..., 6.25 µg/mL). The microorganism suspensions at 10⁶ CFU/mL (colony forming unit/mL) concentration were inoculated to the corresponding wells. The plates were incubated at 36 °C for 24 and 48 h for the bacteria and *C. albicans*, respectively. The MIC values were determined as the lowest concentration that completely inhibited visible growth of the microorganism as detected by unaided eye (Table 3). The structure–antimicrobial activity relationship of the synthesized compounds, based on the structures of the starting compound **2**, which possessed good antimicrobial activity, revealed that the introduction of an arylaminomethyl moiety generally reduced the antimicrobial activity according to the nature of the aryl moiety. Among the arylaminomethyl derivatives **4a–m**, the aryl substituents

Table 3. The minimal inhibitory concentrations (MIC, µg/mL) of compounds **2**, **4c,e,l,m**, **5a,b,d–h**, the broad spectrum antibacterial drug Ciprofloxacin and the antifungal drug Clotrimazole against *S. aureus* ATCC 19433 (*SA*), *B. subtilis* ATCC 6633 (*BS*), *E. coli* ATCC 25922 (*EC*), *P. aeruginosa* ATCC 27853 (*PA*), and *C. albicans* ATCC 753 (*CA*)

Compound no.	Minimal inhibitory concentration (MIC, µg/mL)				
	<i>SA</i>	<i>BS</i>	<i>EC</i>	<i>PA</i>	<i>CA</i>
2	12.5	12.5	50	100	100
4c	100	200	200	200	400
4e	50	50	200	400	>400
4l	50	100	200	200	200
4m	50	50	400	200	400
5a	12.5	12.5	50	50	200
5b	50	50	200	200	200
5d	50	50	200	200	400
5e	25	100	100	200	200
5f	50	50	200	200	400
5g	100	100	400	400	>400
5h	50	100	400	400	>400
Ciprofloxacin	<6.25	<6.25	<6.25	<6.25	NT
Clotrimazole	NT	NT	NT	NT	12.5

(NT): Not tested.

had a great influence on the activity, the 4-chlorophenyl, 2-trifluoromethylphenyl, and 2,5-difluorophenyl derivatives were the most active. The piperazinomethyl derivatives **5a–h** were found to be more active than the arylaminomethyl derivatives **4a–m**. The maximum activity was attained with compound **5a** (*R* = CH₃). Replacement of the methyl group with ethyl, phenyl, 4-fluorophenyl, 2-methoxyphenyl, benzyl, or 2-trifluoromethylbenzyl groups did not reduce the antibacterial activity significantly, but greatly reduced the antifungal activity. Meanwhile, replacement of the methyl group with an ethoxycarbonyl function (**5c**) dramatically reduced the antimicrobial activity.

2.3. In vitro anti-HIV-1 activity

The inhibitory activity of compounds **2**, **4a–m**, and **5a–h** against human immunodeficiency virus type 1 (HIV-1) was determined using the XTT assay in MT-4 cells.³⁷ The method simultaneously determine both antiviral activity and cellular toxicity, showing the net effect of antiviral activity. The method depends on measuring the change in optical density produced by 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) at 450 nm, which is indicative of and proportional to healthy, metabolizing cells. The anti-HIV-1 activity of compounds **2**, **4a–m**, and **5a–h** at 50, 10, and 2 µg/mL concentrations and the cytotoxic doses CD₅₀ are shown in Table 4. The results revealed that the majority of the tested compounds inhibited viral replication at 50 and 10 µg/mL concentrations. Compounds **2** was found to be the most active among the tested compounds, it produced 100%, 43%, and 37% reduction of viral replication at 50, 10, and 2 µg/mL concentrations, respectively. Meanwhile, compounds **4c,f**, and **5a** showed moderate antiviral activity producing more than 10% inhibition of viral replication at 2 µg/mL concentrations. Compounds

Table 4. The anti-HIV-1 activity and cellular toxicity of compounds **2**, **4a–m**, and **5a–h**

Compound no.	%Reduction of HIV-1 ^a			CD ₅₀ ^b (μg/mL)
	50 μg/mL	10 μg/mL	2 μg/mL	
2	100	43	37	68
4a	22	9	0	>100
4b	0	0	0	>100
4c	23	19	14	>100
4d	12	8	0	>100
4e	0	0	0	>100
4f	17	14	13	>100
4g	0	0	0	>100
4h	12	0	0	>100
4i	16	15	5	>100
4j	33	24	5	>100
4k	19	17	7	>100
4l	27	12	5	>100
4m	41	12	0	>100
5a	53	19	11	>100
5b	26	6	0	>100
5c	0	0	0	>100
5d	11	8	6	>100
5e	41	13	5	>100
5f	12	8	0	>100
5g	37	19	0	>100
5h	26	19	9	>100

^a Percentage inhibition of virus replication at each of the indicated concentrations.

^b The cytotoxic dose (the dose which gives 50% inhibition of growth of uninfected cells).

4b, e, g, and **5c** were totally inactive. All the tested compounds were found to be noncytotoxic with CD₅₀ > 100 μg/mL, except compound **2** whose CD₅₀ was 68 μg/mL.

3. Experimental

All melting points (°C, uncorrected) were determined using Fisher–Johns melting point apparatus. Infra red spectra were recorded in KBr disc using Jasco FT/IR 460 Plus spectrometer and expressed in wave number ν (cm⁻¹). NMR spectra were obtained on a Bruker AC 250 FT NMR spectrometer at 250 MHz for ¹H and 62.9 MHz for ¹³C, the chemical shifts are expressed in δ (ppm) downfield from tetramethylsilane (TMS) using CDCl₃ as solvent. Electron impact mass spectra were recorded on a Shimadzu GC–MS–QP 5000 instrument. Elemental analyses (C, H, N, S) were in agreement with the proposed structures within $\pm 0.4\%$ of the theoretical values.

3.1. 5-(1-Adamantyl)-1,3,4-oxadiazoline-2-thione (**2**)

A mixture of adamantane-1-carbohydrazide (19.4 g, 0.1 mol), potassium hydroxide (5.6 g, 0.1 mol) and carbon disulfide (11.4 g, 0.15 mol), in ethanol (200 mL) was heated under reflux with stirring for 10 h and the solvent was distilled in vacuo. The obtained residue was dissolved in water (100 mL), filtered, and the filtrate was acidified with hydrochloric acid. The precipitated crude product was filtered, washed with water, dried, and crystallized from light petroleum (60–80)–CHCl₃ to yield 19.1 g (81%) of **2**. Mp 181–183 °C. IR, ν

(cm⁻¹): 3162 (NH), 2914, 2850 (CH₂, CH), 1604, 1504 (C=N), 1343 (C=S), 1266 (C–O–C). ¹H NMR: δ 1.71–1.76 (m, 6H, adamantane-CH₂), 1.99 (s, 6H, adamantane-CH₂), 2.08 (s, 3H, adamantane-CH), 11.60 (br s, 1H, NH). ¹³C NMR: δ 27.31, 34.47, 35.92, 38.94 (adamantane-C), 170.34 (C=N), 178.27 (C=S). MS m/z (rel. int.): 237 (M⁺+1, 13), 236 (M⁺, 81), 176 (19), 136 (11), 135 (100).

3.2. 5-(1-Adamantyl)-2-ethylthio-1,3,4-oxadiazoles (**3a**)

Potassium hydroxide (0.56 g, 0.01 mol) was added to a solution of 5-(1-adamantyl)-1,3,4-oxadiazoline-2-thione **2** (2.36 g, 0.01 mol) in ethanol (15 mL) and the mixture was heated under reflux for 10 min. Iodoethane (1.56 g, 0.01 mol) was added dropwise and the mixture was heated under reflux for 2 h and the solvent was distilled in vacuo. The obtained residue was washed with water, dried and crystallized. IR, ν (cm⁻¹): 2960 (CH₃, CH₂, CH), 1610, 1413 (C=N), 1252 (C–O–C). ¹H NMR: δ 1.44 (t, 3H, CH₃), 1.78 (s, 6H, adamantane-H), 2.04–2.09 (m, 9H, adamantane-H), 3.19 (q, 2H, CH₂). ¹³C NMR: δ 14.61 (CH₃), 26.75 (CH₂), 27.62, 34.30, 36.17, 39.73 (adamantane-C), 163.25 (C=N), 173.76 (N=C–S). MS m/z (rel. int.): 265 (M⁺+1, 7), 264 (M⁺, 30), 236 (13), 203 (38), 135 (100).

3.3. 5-(1-Adamantyl)-2-(2-aminoethylthio)-1,3,4-oxadiazoles (**3b, c**)

Potassium hydroxide (1.12 g, 0.02 mol) was added to a solution of 5-(1-adamantyl)-1,3,4-oxadiazoline-2-thione **2** (2.36 g, 0.01 mol) in ethanol (15 mL) and the mixture was heated under reflux for 10 min. The appropriate 2-aminoethyl chloride hydrochloride (0.01 mol) was added and the mixture was heated under reflux for 4 h and the solvent was distilled in vacuo. The obtained residue was washed with water, dried, and crystallized. Compound **3b**: IR, ν (cm⁻¹): 2915 (CH₃, CH₂, CH), 1612, 1415 (C=N), 1254 (C–O–C). ¹H NMR: 1.78 (s, 6H, adamantane-H), 2.04 (s, 6H, adamantane-H), 2.08 (s, 3H, adamantane-H), 2.29 (s, 6H, CH₃), 2.68 (t, 2H, SCH₂), 3.33 (t, 2H, NCH₂). ¹³C NMR: 30.59 (CH₃), 27.63, 34.32, 36.18, 39.74 (adamantane-C), 54.04 (NCH₂), 57.76 (SCH₂), 163.57 (C=N), 174.23 (N=C–S). MS m/z (rel. int.): 307 (M⁺, 1), 260 (2), 203 (1), 135 (6), 72 (13), 71 (100), 58 (85). Compound **3c**: IR, ν (cm⁻¹): 2902 (CH₂, CH), 1610, 1415 (C=N), 1250 (C–O–C). ¹H NMR: δ 1.41 (q, 2H, CH₂), 1.53–1.62 (m, 4H, CH₂), 1.78 (s, 6H, adamantane-H), 2.04 (s, 3H, adamantane-H), 2.08 (s, 3H, adamantane-H), 2.43 (t, 4H, N(CH₂)₂), 2.72 (t, 2H, SCH₂), 3.35 (t, 2H, NCH₂). ¹³C NMR: δ 24.13, 25.84, 30.12 (piperidine-C), 27.37, 34.25, 36.13, 39.70 (adamantane-C), 54.13 (NCH₂), 57.34 (SCH₂), 163.90 (C=N), 173.45 (N=C–S). MS m/z (rel. int.): 347 (M⁺, 1), 249 (1), 248 (5), 220 (7), 203 (2), 135 (11), 112 (13), 111 (100), 98 (83).

3.4. 5-(1-Adamantyl)-3-arylaminomethyl-1,3,4-oxadiazoline-2-thiones (**4a–m**)

The appropriate primary aromatic amine (0.01 mol) and 37% formaldehyde solution (1.5 mL) were added to a

solution of 5-(1-adamantyl)-1,3,4-oxadiazoline-2-thione **2** (2.36 g, 0.01 mol) in ethanol (15 mL), and the mixture was stirred at room temperature for 2 h and allowed to stand overnight. The separated precipitate was filtered, washed with cold ethanol, dried, and crystallized. Compound **4a**: IR, ν (cm^{-1}): 3336 (NH), 3034 (Ar-CH), 2909, 2849 (CH_2 , CH), 1604, 1457 ($\text{C}=\text{N}$), 1370 ($\text{C}=\text{S}$), 1258 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.75 (q, 6H, adamantane- CH_2), 1.95 (s, 6H, adamantane- CH_2), 2.08 (s, 3H, adamantane-CH), 5.05 (t, 1H, NH), 5.41 (d, 2H, CH_2), 6.81–6.92 (m, 3H, Ar-H), 7.20 (t, 2H, Ar-H). ^{13}C NMR: δ 27.30, 34.30, 35.91, 38.91 (adamantane-C), 58.32 (CH_2), 114.01, 119.54, 129.19, 144.11 (Ar-C), 168.02 ($\text{C}=\text{N}$), 176.71 ($\text{C}=\text{S}$). MS m/z (rel. int.): 341 (M^+ , 3), 236 (89), 176 (17), 135 (100), 105 (78), 77 (70). Compound **4b**: IR, ν (cm^{-1}): 3332 (NH), 3031 (Ar-CH), 2908, 2849 (CH_2 , CH), 1619, 1456 ($\text{C}=\text{N}$), 1375 ($\text{C}=\text{S}$), 1254 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.69 (q, 6H, adamantane- CH_2), 1.94 (s, 6H, adamantane- CH_2), 2.07 (s, 3H, adamantane-CH), 5.25 (t, 1H, NH), 5.44 (d, 2H, CH_2), 6.74 (q, 1H, Ar-H), 6.95–7.06 (m, 2H, Ar-H), 7.16–7.26 (m, 1H, Ar-H). ^{13}C NMR: δ 27.36, 34.39, 35.97, 38.97 (adamantane-C), 57.61 (CH_2), 114.06, 115.0, 119.44, 124.55, 132.68, 148.09 (Ar-C), 168.24 ($\text{C}=\text{N}$), 176.86 ($\text{C}=\text{S}$). MS m/z (rel. int.): 360 (M^+ +1, 4), 359 (M^+ , 16), 236 (92), 176 (18), 135 (100), 123 (64), 124 (92), 95 (33). Compound **4c**: IR, ν (cm^{-1}): 3337 (NH), 3035 (Ar-CH), 2908, 2850 (CH_2 , CH), 1603, 1462 ($\text{C}=\text{N}$), 1371 ($\text{C}=\text{S}$), 1247 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.68 (q, 6H, adamantane- CH_2), 1.93 (s, 6H, adamantane- CH_2), 2.07 (s, 3H, adamantane-CH), 4.98 (t, 1H, NH), 5.35 (d, 2H, CH_2), 6.79–6.95 (m, 4H, Ar-H). ^{13}C NMR: δ 27.30, 34.33, 35.91, 38.94 (adamantane-C), 58.92 (CH_2), 113.19, 119.89, 140.61, 155.07 (Ar-C), 168.16 ($\text{C}=\text{N}$), 176.75 ($\text{C}=\text{S}$). MS m/z (rel. int.): 360 (M^+ +1, 1), 359 (M^+ , 2), 236 (72), 176 (16), 135 (100), 122 (32), 123 (39), 95 (37). Compound **4d**: IR, ν (cm^{-1}): 3447 (NH), 3068 (Ar-CH), 2909, 2852 (CH_2 , CH), 1602, 1442 ($\text{C}=\text{N}$), 1374 ($\text{C}=\text{S}$), 1249 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.64 (q, 6H, adamantane- CH_2), 1.96 (s, 6H, adamantane- CH_2), 2.10 (s, 3H, adamantane-CH), 5.50 (d, 2H, CH_2), 5.64 (t, 1H, NH), 6.77–6.80 (m, 1H, Ar-H), 7.19–7.24 (m, 2H, Ar-H), 7.29 (d, 1H, Ar-H). ^{13}C NMR: δ 27.43, 34.49, 36.06, 39.04 (adamantane-C), 57.57 (CH_2), 113.19, 117.93, 119.89, 120.20, 129.51, 140.61 (Ar-C), 168.39 ($\text{C}=\text{N}$), 176.89 ($\text{C}=\text{S}$). MS m/z (rel. int.): 377 (M^+ +2, 2), 375 (M^+ , 6), 236 (83), 176 (29), 142 (60), 140 (100), 135 (94), 113 (16), 111 (49). Compound **4e**: IR, ν (cm^{-1}): 3326 (NH), 3042 (Ar-CH), 2906, 2851 (CH_2 , CH), 1604, 1460 ($\text{C}=\text{N}$), 1370 ($\text{C}=\text{S}$), 1249 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.68 (q, 6H, adamantane- CH_2), 1.93 (s, 6H, adamantane- CH_2), 2.07 (s, 3H, adamantane-CH), 5.06 (t, 1H, NH), 5.36 (d, 2H, CH_2), 6.80 (d, 2H, Ar-H), 7.14 (d, 2H, Ar-H). ^{13}C NMR: δ 27.30, 34.35, 35.91, 38.94 (adamantane-C), 58.22 (CH_2), 115.30, 124.46, 129.10, 142.75 (Ar-C), 168.20 ($\text{C}=\text{N}$), 176.77 ($\text{C}=\text{S}$). MS m/z (rel. int.): 377 (M^+ +2, 1), 359 (M^+ , 4), 236 (82), 176 (17), 142 (20), 140 (55), 135 (100), 113 (5), 111 (26). Compound **4f**: IR, ν (cm^{-1}): 3418 (NH), 3055 (Ar-CH), 2902, 2851 (CH_2 , CH), 1600, 1441 ($\text{C}=\text{N}$), 1381 ($\text{C}=\text{S}$), 1250 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.68 (q, 6H, adamantane- CH_2), 1.94 (s, 6H, adamantane- CH_2), 2.07 (s,

3H, adamantane-CH), 5.45 (d, 2H, CH_2), 5.60 (t, 1H, NH), 6.66–6.69 (m, 1H, Ar-H), 7.18–7.27 (m, 2H, Ar-H), 7.42 (d, 1H, Ar-H). ^{13}C NMR: δ 27.34, 34.38, 35.95, 38.95 (adamantane-C), 57.65 (CH_2), 113.23, 120.30, 128.48, 129.26, 132.66, 141.56 (Ar-C), 168.23 ($\text{C}=\text{N}$), 176.79 ($\text{C}=\text{S}$). MS m/z (rel. int.): 421 (M^+ +2, 4), 419 (M^+ , 4), 340 (10), 236 (44), 186 (72), 185 (35), 184 (100), 183 (29), 176 (7), 157 (6), 155 (7), 135 (47). Compound **4g**: IR, ν (cm^{-1}): 3323 (NH), 3028 (Ar-CH), 2903, 2851 (CH_2 , CH), 1596, 1458 ($\text{C}=\text{N}$), 1368 ($\text{C}=\text{S}$), 1248 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.68 (q, 6H, adamantane- CH_2), 1.92 (s, 6H, adamantane- CH_2), 2.06 (s, 3H, adamantane-CH), 5.12 (t, 1H, NH), 5.36 (d, 2H, CH_2), 6.76 (d, 2H, Ar-H), 7.27 (d, 2H, Ar-H). ^{13}C NMR: δ 27.33, 34.36, 36.21, 38.98 (adamantane-C), 58.20 (CH_2), 114.35, 124.88, 132.54, 144.23 (Ar-C), 167.42 ($\text{C}=\text{N}$), 176.62 ($\text{C}=\text{S}$). MS m/z (rel. int.): 421 (M^+ +2, 3), 419 (M^+ , 3), 340 (1), 236 (100), 186 (18), 185 (69), 184 (50), 183 (68), 176 (7), 157 (23), 155 (22), 135 (99). Compound **4h**: IR, ν (cm^{-1}): 3340 (NH), 3044 (Ar-CH), 2912, 2851 (CH_2 , CH), 1622 (NO_2), 1604, 1457 ($\text{C}=\text{N}$), 1354 ($\text{C}=\text{S}$), 1252 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.67 (q, 6H, adamantane- CH_2), 1.96 (s, 6H, adamantane- CH_2), 2.09 (s, 3H, adamantane-CH), 5.44–5.50 (m, 3H, NH and CH_2), 7.20–7.22 (m, 1H, Ar-H), 7.36 (t, 1H, Ar-H), 7.68–7.69 (m, 1H, Ar-H), 7.82 (s, 1H, Ar-H). ^{13}C NMR: δ 27.40, 34.53, 36.02, 39.02 (adamantane-C), 57.74 (CH_2), 108.50, 114.46, 120.06, 130.13, 145.39, 149.31 (Ar-C), 168.50 ($\text{C}=\text{N}$), 177.0 ($\text{C}=\text{S}$). MS m/z (rel. int.): 386 (M^+ , 1), 236 (100), 176 (41), 151 (11), 150 (82), 135 (99). Compound **4i**: IR, ν (cm^{-1}): 3365 (NH), 3042 (Ar-CH), 2908, 2850 (CH_2 , CH), 1602, 1456 ($\text{C}=\text{N}$), 1356 ($\text{C}=\text{S}$), 1253 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.69 (q, 6H, adamantane- CH_2), 1.94 (s, 6H, adamantane- CH_2), 2.08 (s, 3H, adamantane-CH), 5.45 (d, 2H, CH_2), 5.62 (t, 1H, NH), 6.91 (d, 2H, Ar-H), 8.12 (d, 2H, Ar-H). ^{13}C NMR: δ 27.34, 34.50, 35.94, 39.0 (adamantane-C), 56.96 (CH_2), 107.84, 113.01, 126.0, 149.97 (Ar-C), 167.31 ($\text{C}=\text{N}$), 177.22 ($\text{C}=\text{S}$). MS m/z (rel. int.): 387 (M^+ +1, 1), 387 (M^+ , 4), 236 (100), 176 (7), 151 (19), 150 (32), 135 (99). Compound **4j**: IR, ν (cm^{-1}): 3341 (NH), 3025 (Ar-CH), 3002 (CH_3), 2903, 2849 (CH_2 , CH), 1604, 1455 ($\text{C}=\text{N}$), 1364 ($\text{C}=\text{S}$), 1235 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.68 (q, 6H, adamantane- CH_2), 1.92 (s, 6H, adamantane- CH_2), 2.06 (s, 3H, adamantane-CH), 3.74 (s, 3H, OCH_3), 4.85 (t, 1H, NH), 5.35 (d, 2H, CH_2), 6.76–6.85 (m, 4H, Ar-H). ^{13}C NMR: δ 27.34, 34.33, 35.95, 38.97 (adamantane-C), 55.52 (OCH_3), 59.44 (CH_2), 114.75, 115.71, 137.81, 153.54 (Ar-C), 168.08 ($\text{C}=\text{N}$), 176.72 ($\text{C}=\text{S}$). MS m/z (rel. int.): 371 (M^+ , 2), 236 (61), 176 (6), 136 (7), 135 (100), 120 (38). Compound **4k**: IR, ν (cm^{-1}): 3374 (NH), 3021 (Ar-CH), 2911, 2850 (CH_2 , CH), 2210 (CN), 1608, 1437 ($\text{C}=\text{N}$), 1376 ($\text{C}=\text{S}$), 1266 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.72 (q, 6H, adamantane- CH_2), 1.96 (s, 6H, adamantane- CH_2), 2.10 (s, 3H, adamantane-CH), 5.50 (d, 2H, CH_2), 5.77 (t, 1H, NH), 6.86 (t, 1H, Ar-H), 7.31 (d, 1H, Ar-H), 7.47–7.51 (m, 2H, Ar-H). ^{13}C NMR: δ 27.41, 34.55, 36.03, 39.02 (adamantane-C), 56.94 (CH_2), 97.77 (CN), 112.72, 117.13, 119.35, 132.94, 134.50, 147.06 (Ar-C), 168.66 ($\text{C}=\text{N}$), 176.94 ($\text{C}=\text{S}$). MS m/z (rel. int.): 366 (M^+ , 8), 236 (100), 176 (29), 135 (97), 131 (58), 102 (42). Compound

4l: IR, ν (cm^{-1}): 3336 (NH), 3011 (Ar-CH), 2908, 2852 (CH_2 , CH), 1592, 1455 ($\text{C}=\text{N}$), 1364 ($\text{C}=\text{S}$), 1324 (CF_3), 1246 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.73 (q, 6H, adamantane- CH_2), 1.96 (s, 6H, adamantane- CH_2), 2.10 (s, 3H, adamantane-CH), 5.49 (d, 2H, CH_2), 5.65 (t, 1H, NH), 6.89 (t, 1H, Ar-H), 7.28–7.31 (m, 1H, Ar-H), 7.45–7.52 (m, 2H, Ar-H). ^{13}C NMR: δ 27.42, 34.51, 35.92, 39.03 (adamantane-C), 57.47 (CH_2), 113.94, 118.86, 125.78, 126.82, 133.33, 142.26 (Ar-C), 115.13 (CF_3), 168.50 ($\text{C}=\text{N}$), 176.96 ($\text{C}=\text{S}$). MS m/z (rel. int.): 410 ($\text{M}^+ + 1$, 1), 409 (M^+ , 5), 236 (61), 176 (14), 174 (82), 173 (40), 154 (43), 145 (32), 135 (100). Compound **4m**: IR, ν (cm^{-1}): 3327 (NH), 3031 (Ar-CH), 2907, 2850 (CH_2 , CH), 1613, 1462 ($\text{C}=\text{N}$), 1370 ($\text{C}=\text{S}$), 1250 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.73 (q, 6H, adamantane- CH_2), 1.97 (s, 6H, adamantane- CH_2), 2.10 (s, 3H, adamantane-CH), 5.37 (t, 1H, NH), 5.43 (d, 2H, CH_2), 6.42–6.47 (m, 1H, Ar-H), 6.92–6.95 (m, 1H, Ar-H), 6.98–7.02 (m, 1H, Ar-H). ^{13}C NMR: δ 27.42, 34.52, 36.05, 39.03 (adamantane-C), 57.22 (CH_2), 101.61, 104.71, 115.22, 134.02, 146.80, 158.45 (Ar-C), 168.45 ($\text{C}=\text{N}$), 177.0 ($\text{C}=\text{S}$). MS m/z (rel. int.): 378 ($\text{M}^+ + 1$, 2), 377 (M^+ , 8), 236 (94), 176 (25), 163 (8), 141 (93), 135 (100), 113 (42), 93 (36), 79 (48).

3.5. 5-(1-Adamantyl)-3-(4-substituted-1-piperazinylmethyl)-1,3,4-oxadiazoline-2-thiones (**5a–h**)

A mixture of 5-(1-adamantyl)-1,3,4-oxadiazoline-2-thione **2** (2.36 g, 0.01 mol), the appropriate *N*-substituted piperazine (0.01 mol) and 37% formaldehyde solution (1.5 mL), in ethanol (15 mL), was stirred at room temperature for 2 h and allowed to stand overnight. The crude products were either precipitated or it was necessary to add water (5 mL) in cases of compounds **5a–c** to be precipitated. The crude products were filtered, washed with water, dried, and crystallized. Compound **5a**: IR, ν (cm^{-1}): 2907, 2850 (CH_3 , CH_2 , CH), 1605, 1440 ($\text{C}=\text{N}$), 1366 ($\text{C}=\text{S}$), 1253 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.70 (q, 6H, adamantane- CH_2), 1.97 (s, 6H, adamantane- CH_2), 1.98 (s, 3H, adamantane-CH), 2.27 (s, 3H, CH_3), 2.43 (t, 4H, piperazine- CH_2), 2.82 (t, 4H, piperazine- CH_2), 4.98 (s, 2H, CH_2). ^{13}C NMR: δ 27.36, 34.23, 35.98, 38.98 (adamantane-C), 45.90 (CH_3), 49.91 (piperazine- CH_2), 54.79 (piperazine- CH_2), 69.66 (CH_2), 167.58 ($\text{C}=\text{N}$), 178.39 ($\text{C}=\text{S}$). MS m/z (rel. int.): 348 (M^+ , 1), 236 (2), 135 (6), 114 (8), 113 (100), 70 (8). Compound **5b**: IR, ν (cm^{-1}): 2906, 2847 (CH_3 , CH_2 , CH), 1610, 1445 ($\text{C}=\text{N}$), 1361 ($\text{C}=\text{S}$), 1243 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.06 (t, 3H, CH_3), 1.72 (q, 6H, adamantane- CH_2), 1.97 (s, 6H, adamantane- CH_2), 2.09 (s, 3H, adamantane-CH), 2.40 (q, 2H, CH_2CH_3), 2.47 (t, 4H, piperazine- CH_2), 2.87 (t, 4H, piperazine- CH_2), 4.99 (s, 2H, CH_2). ^{13}C NMR: δ 11.93 (CH_3), 27.32, 34.34, 36.10, 38.95 (adamantane-C), 50.06 (CH_2CH_3), 52.28 (piperazine- CH_2), 52.62 (piperazine- CH_2), 69.82 (CH_2), 167.72 ($\text{C}=\text{N}$), 178.59 ($\text{C}=\text{S}$). MS m/z (rel. int.): 362 (M^+ , 1), 236 (10), 176 (4), 135 (32), 127 (100), 11 (5), 98 (13), 84 (54). Compound **5c**: IR, ν (cm^{-1}): 2995, 2925, 2855 (CH_3 , CH_2 , CH), 1692 ($\text{C}=\text{O}$), 1607, 1455 ($\text{C}=\text{N}$), 1362 ($\text{C}=\text{S}$), 1246 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.25 (t, 3H, CH_3), 1.74 (q, 6H, adamantane- CH_2), 1.99 (s, 6H, adamantane- CH_2), 2.11 (s, 3H, adamantane-CH),

2.77 (t, 4H, piperazine- CH_2), 3.49 (t, 4H, piperazine- CH_2), 4.11 (q, 2H, CH_2CH_3), 4.99 (s, 2H, CH_2). ^{13}C NMR: δ 14.65 (CH_3), 27.45, 34.40, 36.08, 39.09 (adamantane-C), 43.20 (CH_2CH_3), 50.08 (piperazine- CH_2), 61.45 (piperazine- CH_2), 70.01 (CH_2), 155.41 ($\text{C}=\text{O}$), 167.96 ($\text{C}=\text{N}$), 178.56 ($\text{C}=\text{S}$). MS m/z (rel. int.): 406 (M^+ , 1), 333 (1), 236 (7), 176 (3), 172 (24), 171 (100), 143 (11), 135 (25), 97 (17), 70 (19). **5d**: IR, ν (cm^{-1}): 3013 (Ar-CH), 2905, 2855 (CH_2 , CH), 1600, 1439 ($\text{C}=\text{N}$), 1355 ($\text{C}=\text{S}$), 1242 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.75 (q, 6H, adamantane- CH_2), 2.01 (s, 6H, adamantane- CH_2), 2.12 (s, 3H, adamantane-CH), 2.98 (t, 4H, piperazine- CH_2), 3.20 (t, 4H, piperazine- CH_2), 5.06 (s, 2H, CH_2), 6.88–6.95 (m, 3H, Ar-H), 7.27 (t, 2H, Ar-H). ^{13}C NMR: δ 27.47, 34.40, 36.10, 39.12 (adamantane-C), 49.36 (piperazine- CH_2), 50.26 (piperazine- CH_2), 69.86 (CH_2), 116.43, 120.15, 129.17, 151.22 (Ar-C), 167.91 ($\text{C}=\text{N}$), 178.62 ($\text{C}=\text{S}$). MS m/z (rel. int.): 410 (M^+ , 4), 236 (22), 175 (100), 174 (12), 162 (15), 135 (52), 132 (42), 120 (46), 77 (42). Compound **5e**: IR, ν (cm^{-1}): 3055 (Ar-CH), 2907, 2851, 2824 (CH_2 , CH), 1611, 1446 ($\text{C}=\text{N}$), 1361 ($\text{C}=\text{S}$), 1233 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.75 (q, 6H, adamantane- CH_2), 2.0 (s, 6H, adamantane- CH_2), 2.12 (s, 3H, adamantane-CH), 2.98 (t, 4H, piperazine- CH_2), 3.11 (t, 4H, piperazine- CH_2), 5.05 (s, 2H, CH_2), 6.87–6.90 (m, 2H, Ar-H), 6.95–7.0 (m, 2H, Ar-H). ^{13}C NMR: δ 27.46, 34.40, 36.09, 39.12 (adamantane-C), 50.25 (piperazine- CH_2), 50.35 (piperazine- CH_2), 69.80 (CH_2), 115.50, 118.18, 147.85, 158.33 (Ar-C), 167.92 ($\text{C}=\text{N}$), 178.62 ($\text{C}=\text{S}$). MS m/z (rel. int.): 428 (M^+ , 3), 236 (17), 193 (100), 178 (8), 150 (36), 135 (46), 122 (31), 95 (17), 70 (60). Compound **5f**: IR, ν (cm^{-1}): 3061 (Ar-CH), 2904, 2832 (CH_3 , CH_2 , CH), 1608, 1446 ($\text{C}=\text{N}$), 1372 ($\text{C}=\text{S}$), 1243 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.75 (q, 6H, adamantane- CH_2), 2.02 (s, 6H, adamantane- CH_2), 2.12 (s, 3H, adamantane-CH), 3.04–3.10 (m, 8H, piperazine- CH_2), 3.87 (s, 3H, OCH_3), 5.06 (s, 2H, CH_2), 6.87 (d, 1H, Ar-H), 6.92–6.98 (m, 2H, Ar-H), 7.02–7.05 (m, 1H, Ar-H). ^{13}C NMR: δ 27.49, 34.39, 36.13, 39.09 (adamantane-C), 50.40 (piperazine- CH_2), 50.69 (piperazine- CH_2), 55.29 (OCH_3), 70.08 (CH_2), 110.90, 118.26, 120.91, 123.23, 141.02, 152.16 (Ar-C), 167.82 ($\text{C}=\text{N}$), 178.70 ($\text{C}=\text{S}$). MS m/z (rel. int.): 440 (M^+ , 1), 236 (75), 192 (32), 191 (3), 176 (16), 150 (71), 135 (100), 107 (13), 79 (33). Compound **5g**: IR, ν (cm^{-1}): 3016 (Ar-CH), 2905, 2851 (CH_2 , CH), 1607, 1440 ($\text{C}=\text{N}$), 1359 ($\text{C}=\text{S}$), 1246 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.74 (q, 6H, adamantane- CH_2), 1.99 (s, 6H, adamantane- CH_2), 2.11 (s, 3H, adamantane-CH), 2.49 (t, 4H, piperazine- CH_2), 2.85 (t, 4H, piperazine- CH_2), 3.52 (s, 2H, $\text{CH}_2\text{C}_6\text{H}_5$), 4.98 (s, 2H, CH_2), 7.25–7.34 (m, 5H, Ar-H). ^{13}C NMR: δ 27.48, 34.36, 36.11, 39.11 (adamantane-C), 50.20 (piperazine- CH_2), 52.94 (piperazine- CH_2), 63.14 ($\text{CH}_2\text{C}_6\text{H}_5$), 69.99 (CH_2), 127.16, 128.16, 129.29, 137.74 (Ar-C), 167.76 ($\text{C}=\text{N}$), 178.62 ($\text{C}=\text{S}$). MS m/z (rel. int.): 424 (M^+ , 1), 236 (14), 189 (100), 176 (8), 158 (16), 135 (37), 98 (19), 91 (70), 70 (41). Compound **5h**: IR, ν (cm^{-1}): 3097 (Ar-CH), 2907, 2854, 2813 (CH_2 , CH), 1607, 1440 ($\text{C}=\text{N}$), 1359 ($\text{C}=\text{S}$), 1312 (CF_3), 1244 ($\text{C}-\text{O}-\text{C}$). ^1H NMR: δ 1.76 (q, 6H, adamantane- CH_2), 2.02 (s, 6H, adamantane- CH_2), 2.12 (s, 3H, adamantane-CH), 2.52 (t, 4H, piperazine- CH_2), 2.85 (t,

4H, piperazine-CH₂), 3.67 (s, 2H, CH₂C₆H₄), 4.99 (s, 2H, CH₂), 7.32 (t, 1H, Ar-H), 7.50 (t, 1H, Ar-H), 7.62 (d, 1H, Ar-H), 7.75 (d, 1H, Ar-H). ¹³C NMR: δ 27.48, 34.39, 36.11, 39.13 (adamantane-C), 50.31 (piperazine-CH₂), 53.09 (piperazine-CH₂), 58.12 (CH₂C₆H₅), 70.08 (CH₂), 123.35 (CF₃), 125.52, 126.78, 127.70, 130.26, 131.72, 137.53 (Ar-C), 167.84 (C=N), 178.64 (C=S). MS *m/z* (rel. int.): 492 (M⁺, 1), 257 (100), 236 (6), 214 (15), 176 (5), 159 (46), 135 (30), 98 (17), 91 (9), 70 (51).

Acknowledgements

The authors would like to express their sincere thanks to Prof. W. El-Naggar, Microbiology department, Faculty of Pharmacy, University of Mansoura, Egypt, for carrying out the antimicrobial testing, and Dr. Nils Gunnar Johansson, Medivir AB, Huddinge, Sweden, for carrying out the anti-HIV-1 testing. The distinguished scholar award of the Arab fund for economic and social development, Kuwait, to A. A. El-Emam is greatly appreciated.

References and notes

- Vernier, V. G.; Harmon, J. B.; Stump, J. M.; Lynes, T. E.; Marvel, J. P. *Toxicol. Appl. Pharmacol.* **1969**, *15*, 642.
- Rabinovich, S.; Baldini, J. T.; Bannister, R. *Am. J. Med. Sci.* **1969**, *257*, 328.
- Tilley, T. W.; Levitan, P.; Kramer, M. J. *J. Med. Chem.* **1979**, *22*, 1009.
- Scherm, A.; Peteri, D. Ger. Offen. 1,941,218, 1971; *Chem. Abstr.* **1971**, *74*, 99516b.
- Kolocouris, N.; Foscolos, G. B.; Kolocouris, A.; Marakos, P.; Pouli, N.; Fytas, G.; Ikeda, S.; De Clercq, E. *J. Med. Chem.* **1994**, *37*, 2896.
- Stylianakis, I.; Kolocouris, A.; Kolocouris, N.; Fytas, G.; Foscolos, G. B.; Padalko, E.; Neyts, J.; De Clercq, E. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 1699.
- Burstein, M. E.; Serbin, A. V.; Khakhulina, T. V.; Alymova, I. V.; Stotskaya, L. L.; Bogdan, O. P.; Manukchina, E. E.; Jdanov, V. V.; Sharova, N. K. *Antiviral Res.* **1999**, *41*, 135.
- Lange, W.; Masihi, K. N. Ger. Offen. 3,921,062, 1990; *Chem. Abstr.* **1991**, *114*, 115076u.
- VanDerpooten, K.; Balzarini, J.; De Clercq, E.; Poupaert, J. H. *Biomed. Pharmacother.* **1997**, *51*, 464.
- Maj, J.; Sowińska, H.; Baran, L.; Sarnek, J. *Eur. J. Pharmacol.* **1974**, *26*, 9.
- Cox, B.; Tha, S. J. *Eur. J. Pharmacol.* **1975**, *30*, 344.
- Millet, V. M.; Dreisbach, M.; Bryson, Y. T. *Antimicrob. Agents Chemother.* **1982**, *21*, 1.
- Abou-Gharbia, M. A.; Childer, W. E.; Fletcher, H.; McGaughey, G.; Patel, U.; Webb, M. B.; Tardley, J.; Andree, T.; Boast, C.; Kucharik, R. J.; Marquis, K.; Morris, H.; Scerni, R.; Moyer, J. *J. Med. Chem.* **1999**, *42*, 5077.
- Dolin, R.; Reichman, R. C.; Madore, H. P.; Maynard, R.; Linton, P. M.; Webber-Jones, J. *N. Engl. J. Med.* **1982**, *307*, 580.
- Orzeszko, A.; Kamińska, B.; Starościak, B. *J. Il Farmaco* **2002**, *57*, 619.
- Antoniadou-Vyza, E.; Tsitsa, P.; Hytioglou, E.; Tsantili-Kakoulidou, A. *Eur. J. Med. Chem.* **1996**, *31*, 105.
- Wang, J.-J.; Wang, S.-S.; Lee, Ch.-F.; Chung, M.-A.; Chern, Y.-T. *Chemotherapy* **1997**, *43*, 182.
- Papadaki-Valiraki, A.; Papakonstantinou-Garoufalias, S.; Makaros, P.; Chytyroglou-Lada, A.; Hosoya, M.; Balzarini, J.; De Clercq, E. *Il Farmaco* **1993**, *48*, 1091.
- El-Emam, A. A. *Chin. Pharm. J.* **1990**, *42*, 309.
- Krimmel, C. P. U.S. Patent 3,374,244, 1968; *Chem. Abstr.* **1968**, *69*, 35575t.
- Narayanan, V. L.; Setescak, L. L. U.S. Patent 3,951,950, 1976; *Chem. Abstr.* **1977**, *85*, 21153x.
- Georgiev, V., St.; Mullen, G. B. U.S. Patent 4,549,014, 1985; *Chem. Abstr.* **1986**, *104*, 129916y.
- El-Emam, A. A.; Ibrahim, T. M. *Arzneim. Forsch./Drug Res.* **1991**, *41*, 1260.
- Georgiev, V., St.; Radov, L. A.; Kinsolving, C. R.; Griffith, R. C.; Zazulak, W. I.; Kamp, D. K.; Trusso, L. A.; Mack, R. A. *Eur. J. Med. Chem.* **1986**, *21*, 315.
- Küçüküzümlü, Ş. G.; Oruç, E. E.; Rollas, S.; Şahin, F.; Özbek, A. *Eur. J. Med. Chem.* **2002**, *37*, 197.
- Ateş, Ö.; Kocabalkanli, A.; Cesur, N.; Ötük, G. *Il Farmaco* **1998**, *53*, 541.
- Jakubkienė, V.; Burbulienė, M. M.; Mekuškienė, G.; Udrėnaitė, E.; Gaidelis, G.; Vainilavičius, P. *Il Farmaco* **2003**, *58*, 323.
- Amir, M.; Shikla, K. *Eur. J. Med. Chem.* **2004**, *39*, 535.
- Romero, D. L.; Morge, R. A.; Biles, C.; Berrios-Pena, N.; May, P. D.; Palmer, J. R.; Johnson, P. D.; Smith, H. W.; Busso, M.; Tan, C.-K.; Voorman, R. L.; Reusser, F.; Althaus, I. W.; So, A. G.; Resnick, L.; Tarpley, W. G.; Aristoff, P. A. *J. Med. Chem.* **1994**, *37*, 999.
- Romero, D. L.; Olmsted, R. A.; Poel, T. J.; Morge, R. A.; Biles, C.; Keiser, B. J.; Kopta, L. A.; Friis, J. M.; Hosley, J. D.; Stefanski, K. J.; Wishka, D. G.; Evans, D. B.; Morris, J.; Stehle, R. G.; Sharma, S. K.; Yagi, Y.; Voorman, R. L.; Adam, W. J.; Tarpley, W. G.; Thomas, R. C. *J. Med. Chem.* **1996**, *39*, 3769.
- El-Emam, A. A.; Moustafa, M. A.; Abdelal, A. M.; El-Ashmawy, M. B. *Chin. Pharm. J.* **1993**, *45*, 101.
- El-Emam, A. A.; Lehmann, J. *Monatsh. Chem.* **1994**, *125*, 587.
- El-Emam, A. A.; Lehmann, J. *Phosphorus, Sulfur Silicon Relat. Elem.* **1997**, *121*, 473.
- Ficarra, R.; Ficarra, P.; Tommasini, A.; Fenech, G.; Pizzimenti, F. C.; Bisignano, G. *Boll. Chim. Farm.* **1984**, *123*, 317.
- National Committee for Clinical Laboratory Standards (NCCLS) Approved standard document M-7A, Villanova, PA, 1985.
- Murray, P. R.; Baron, E. J.; Pfaller, M. A.; Tenover, F. C.; Tenover, R. H. In *Manual of Clinical Microbiology*; Wood, G. L., Washington, J. A., Eds. *Am. Soc. Microbiol.*; Washington, DC, 1995.
- Ahlgren, C.; Backro, K.; Bell, F. W.; Cantrell, A. S.; Clemens, M.; Colacino, J. M.; Deeter, J. B.; Engelhardt, J. A.; Hogberg, M.; Jaskunas, S. R.; Johansson, N. G.; Jordan, C. L.; Kasher, J. S.; Kinnick, M. D.; Lind, P.; Lopez, C.; Morin, J. A. M., Jr.; Muesing, M. A.; Noreen, R.; Oberg, B.; Paget, C. J., Jr.; Palkowitz, J. A.; Parrish, C. A.; Pranc, P.; Rippey, M. K.; Rydergard, C.; Sahlberg, C.; Swanson, S.; Ternansky, R. J.; Unge, T.; Vasileff, R. T.; Vrang, L.; West, S. L.; Zhang, H.; Zhou, X. X. *Antimicrob. Agents Chemother.* **1995**, *39*, 1329.